Overall, we demonstrated that HCC tumors are vulnerable to proteasome inhibition and that rationally designed combination of ixazomib and dinaciclib is effective in suppressing HCC tumor growth and proliferation through mechanisms involving increased JNK activity. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.